User login
Key clinical point: The risk for breast cancer (BC) was significantly elevated in female 5-year survivors of Hodgkin lymphoma (HL) who were treated with doxorubicin between the ages of 15 and 50 years.
Major finding: The risk for BC was 1.4 times higher (95% CI 1.04-1.9) in survivors of HL who did vs did not receive doxorubicin, with the risk increasing further in survivors who received a cumulative doxorubicin dose > 200 mg/m2 (adjusted hazard ratio 1.5; 95% CI 1.08-2.1). In fact, every 100 mg/m2 increase in doxorubicin dose increased the risk for BC by 1.18 times (95% CI 1.05-1.32).
Study details: Findings are from a cohort study including 5-year survivors of HL (n = 1964) who received treatment between the ages of 15 and 50 years, of whom 1113 patients received doxorubicin.
Disclosures: This study was supported by grants from the Dutch Cancer Society, Netherlands. Five authors declared receiving honoraria, research funding, travel, accommodations, or other expenses from or serving in consulting or advisory roles or as speakers' bureau members for various sources.
Source: Neppelenbroek SIM, Geurts YM, Aleman BMP, et al. Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma. J Clin Oncol. 2024 (Feb 15). doi: 10.1200/JCO.23.01386 Source
Key clinical point: The risk for breast cancer (BC) was significantly elevated in female 5-year survivors of Hodgkin lymphoma (HL) who were treated with doxorubicin between the ages of 15 and 50 years.
Major finding: The risk for BC was 1.4 times higher (95% CI 1.04-1.9) in survivors of HL who did vs did not receive doxorubicin, with the risk increasing further in survivors who received a cumulative doxorubicin dose > 200 mg/m2 (adjusted hazard ratio 1.5; 95% CI 1.08-2.1). In fact, every 100 mg/m2 increase in doxorubicin dose increased the risk for BC by 1.18 times (95% CI 1.05-1.32).
Study details: Findings are from a cohort study including 5-year survivors of HL (n = 1964) who received treatment between the ages of 15 and 50 years, of whom 1113 patients received doxorubicin.
Disclosures: This study was supported by grants from the Dutch Cancer Society, Netherlands. Five authors declared receiving honoraria, research funding, travel, accommodations, or other expenses from or serving in consulting or advisory roles or as speakers' bureau members for various sources.
Source: Neppelenbroek SIM, Geurts YM, Aleman BMP, et al. Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma. J Clin Oncol. 2024 (Feb 15). doi: 10.1200/JCO.23.01386 Source
Key clinical point: The risk for breast cancer (BC) was significantly elevated in female 5-year survivors of Hodgkin lymphoma (HL) who were treated with doxorubicin between the ages of 15 and 50 years.
Major finding: The risk for BC was 1.4 times higher (95% CI 1.04-1.9) in survivors of HL who did vs did not receive doxorubicin, with the risk increasing further in survivors who received a cumulative doxorubicin dose > 200 mg/m2 (adjusted hazard ratio 1.5; 95% CI 1.08-2.1). In fact, every 100 mg/m2 increase in doxorubicin dose increased the risk for BC by 1.18 times (95% CI 1.05-1.32).
Study details: Findings are from a cohort study including 5-year survivors of HL (n = 1964) who received treatment between the ages of 15 and 50 years, of whom 1113 patients received doxorubicin.
Disclosures: This study was supported by grants from the Dutch Cancer Society, Netherlands. Five authors declared receiving honoraria, research funding, travel, accommodations, or other expenses from or serving in consulting or advisory roles or as speakers' bureau members for various sources.
Source: Neppelenbroek SIM, Geurts YM, Aleman BMP, et al. Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma. J Clin Oncol. 2024 (Feb 15). doi: 10.1200/JCO.23.01386 Source